Systemic active immunotherapy is shifting from the middle ages to a renaissance period L. OlssonG. Mathé Editorials Pages: 137 - 138
Systemic active immunotherapy is shifting from the middle ages to a renaissance period L. OlssonG. Mathé Editorials Pages: 139 - 140
The relationship between antigenic strength and success in immunotherapy A. E. Reif Guest Editorial Pages: 141 - 142
In vitro assays of immunocompetence in patients with lung cancer treated with levamisole S. H. GolubE. C. Holmes Original Articles Pages: 143 - 149
Immune cytolysis of human malignant melanoma by antibody to oncofetal antigen I (OFA-I) N. SidellR. F. IrieD. L. Morton Original Articles Pages: 151 - 155
The effects of experimental conditions on the expression of in vitro-mediated tumor cytotoxicity mediated by murine macrophages A. RazW. E. FoglerI. J. Fidler Original Articles Pages: 157 - 163
Active specific immunotherapy of residual micrometastasis M. G. Hanna Jr.J. S. BrandhorstL. C. Peters Original Articles Pages: 165 - 173
Immunologic function during adjuvant BCG immunotherapy for malignant melanoma: Induction of anergy A. S. CoatesR. G. KloppP. P. Carbone Original Articles Pages: 175 - 179
Natural killer-like activity induced in spleen by IP injection of BCG Y. PiochM. GerberB. Serrou Original Articles Pages: 181 - 184
Immunotherapy with tumor vaccine, BCG, and normal plasma during radiation-reduced tumor immunity J. Vaage Original Articles Pages: 185 - 189
Adjuvant immunotherapy with levamisole in resectable lung cancer W. K. AmeryJ. CosemansR. W. Veldhuizen Original Articles Pages: 191 - 198
Disseminated BCG infection in BCG immunotherapy M. RahimaM. TopilskyZ. Keinan Letter To The Editor Pages: 199 - 200
